<DOC>
	<DOCNO>NCT00083616</DOCNO>
	<brief_summary>The purpose study determine panitumumab clinically meaningful anti-tumor activity patient metastatic colorectal cancer develop progressive disease relapse prior fluoropyrimidine , irinotecan oxaliplatin chemotherapy .</brief_summary>
	<brief_title>Evaluating Panitumumab ( ABX-EGF ) Monotherapy Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine , Irinotecan , Oxaliplatin Chemotherapy</brief_title>
	<detailed_description>Panitumumab administer every 2 week participant develop progressive disease , unable tolerate panitumumab , discontinue treatment reason ( eg , administrative decision ) . Participants attend safety follow-up visit 4 week last panitumumab infusion . Participants subsequently contact every 3 month last panitumumab infusion month 24 ass disease status survival .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologic diagnosis colorectal adenocarcinoma ( diagnostic tissue obtain tissue biopsy ) Metastatic colorectal carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Documented evidence disease progression , follow treatment , fluoropyrimidine , irinotecan oxaliplatin chemotherapy metastatic colorectal cancer Radiographic documentation disease progression within 6 month follow recent chemotherapy regimen require Bidimensionally measurable disease Tumor express epidermal growth factor receptor ( EGFr ) immunohistochemistry At least 2 3 prior chemotherapy regimens metastatic colorectal cancer Adequate hematologic , renal hepatic function Symptomatic brain metastasis require treatment Patient history interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis Use systemic chemotherapy radiotherapy within 30 day enrollment Prior epidermal growth factor receptor target agent Prior antitumor therapy include prior experimental agent approve antitumor small molecule biologics short ( less 1 week ) serum halflife within 30 day enrollment , prior experimental approve protein longer serum halflife ( e.g. , AvastinTM ) within 6 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>EGFr</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>ABX-EGF</keyword>
	<keyword>Immunex</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Abgenix</keyword>
	<keyword>Amgen</keyword>
</DOC>